インフルエンザ治療の世界市場:製品種類別(ペラミビル、ザナミビル、リン酸オセルタミビル、バロキサビルマルボキシル、その他)、流通経路別

◆英語タイトル:Influenza Treatment Market by Product Type (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and Others) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Others), Global Opportunity Analysis and Industry Forecast, 2019–2026
◆商品コード:AMR20JN080
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2020年3月
◆ページ数:194
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,370 ⇒換算¥558,480見積依頼/購入/質問フォーム
5 UserUSD6,450 ⇒換算¥670,800見積依頼/購入/質問フォーム
Enterprise UserUSD8,995 ⇒換算¥935,480見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、インフルエンザ治療の世界市場を調査・分析することにより、イントロダクション、エグゼクティブサマリー、市場概要、製品種類別(ペラミビル、ザナミビル、リン酸オセルタミビル、バロキサビルマルボキシル、その他)分析、流通経路別分析、地域別、企業情報と今後の方向性を明らかに致します。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・インフルエンザ治療の世界市場:製品種類別(ペラミビル、ザナミビル、リン酸オセルタミビル、バロキサビルマルボキシル、その他)
・インフルエンザ治療の世界市場:流通経路別
・地域別
・企業情報
【レポートの概要】

The global protein expression market was valued at $2,121 million in 2018 and is projected to reach $4,611 million by 2026, registering a CAGR of 10.2% from 2019 to 2026.
Protein expression refers to a biotechnological process of generating specific protein, typically attained by manipulation of gene expression in an organism such that it expresses large amounts of a recombinant gene. The development of genetic engineering and recombinant technologies has opened many possibilities of expression and isolation of heterologous proteins for research, clinical, and industrial purposes. Considerable advances in biotechnology have enabled expression and isolation of recombinant proteins in large scale. One of the major achievements is the development of recombinant proteins capable of entering a cell. Such developments lead to completely new opportunities in therapeutic medicine by targeting intracellular mechanisms or by substituting intracellularly operating enzymes though therapeutic protein. The first expression platform established was prokaryotic system through Escherichia coli. This was followed by development of other expression systems including yeast, algae, insect, and mammalian.
The factors that boost the growth of the protein expression market include surge in geriatric population and increase in prevalence of chronic diseases such as cancer. Moreover, increase in spending on protein research also fuel the growth of the protein expression market. However, high monetary inputs associated with the production of protein products restrict the growth of the market. In addition, significant shortage of trained healthcare professionals and lack of local expertise also restrains the market. Conversely, emergence of microfluids, along with growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.
The global protein expression market is segmented on the basis of product, application, and region. On the basis of product, it is divided into reagents, expression vectors, competent cells, instruments, and services. By application, it is divided into therapeutic, industrial, and research. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, the UK, Italy, Spain, France, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific) and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current protein expression market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment
• The market forecast is studied from 2019 to 2026
• The market size and estimations are based on a comprehensive analysis of key developments in the industry
• A qualitative analysis based on innovative products facilitates strategic business planning
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
KEY MARKET SEGMENTS
By Product
• Reagents
• Expression vectors
• Competent cells
• Instruments
• Services
By Application
• Therapeutic
• Industrial
• Research
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Rest of Asia-Pacific
• LAMEA
o Latin America
o Middle-East
o Rest of LAMEA

【レポートの目次】

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments

1.2.1. List of key players profiled in the report

1.3. Research methodology

1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Top player positioning

3.2.1. Top investment pockets

3.3. Key forces shaping influenza treatment industry/market
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Surge in incidences of influenza across the globe
3.4.1.2. Increase in healthcare expenditure worldwide
3.4.1.3. Rise in R&D investments for discovery of new drugs

3.4.2. Restraint

3.4.2.1. Presence of substitutes for the treatment of influenza

3.4.3. Opportunity

3.4.3.1. High growth potential in developing economies

3.4.4. Impact Analysis

CHAPTER 4: INFLUENZA TREATMENT MARKET, BY PRODUCT TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Peramivir

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Zanamivir

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Oseltamivir Phosphate

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Baloxavir Marboxil

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

4.6. Other products

4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

CHAPTER 5: INFLUENZA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

5.1. Overview

5.1.1. Market size and forecast

5.2. Retail Pharmacy

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Hospital Pharmacy

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Others

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

CHAPTER 6: INFLUENZA TREATMENT MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends and opportunities
6.2.2. Market analysis, by country

6.2.2.1. U.S.

6.2.2.1.1. U.S. market size and forecast, by product type
6.2.2.1.2. U.S. market size and forecast, by distribution channel

6.2.2.2. Canada

6.2.2.2.1. Canada market size and forecast, by product type
6.2.2.2.2. Canada market size and forecast, by distribution channel

6.2.2.3. Mexico

6.2.2.3.1. Mexico market size and forecast, by product type
6.2.2.3.2. Mexico market size and forecast, by distribution channel

6.2.3. North America market size and forecast, by product type
6.2.4. North America market size and forecast, by distribution channel

6.3. Europe

6.3.1. Key market trends and opportunities
6.3.2. Market analysis, by country

6.3.2.1. Germany

6.3.2.1.1. Germany market size and forecast, by product type
6.3.2.1.2. Germany market size and forecast, by distribution channel

6.3.2.2. France

6.3.2.2.1. France market size and forecast, by product type
6.3.2.2.2. France market size and forecast, by distribution channel

6.3.2.3. UK

6.3.2.3.1. UK market size and forecast, by product type
6.3.2.3.2. UK market size and forecast, by distribution channel

6.3.2.4. Italy

6.3.2.4.1. Italy market size and forecast, by product type
6.3.2.4.2. Italy market size and forecast, by distribution channel

6.3.2.5. Rest of Europe

6.3.2.5.1. Rest of Europe market size and forecast, by product type
6.3.2.5.2. Rest of Europe market size and forecast, by distribution channel

6.3.3. Europe market size and forecast, by product type
6.3.4. Europe market size and forecast, by distribution channel

6.4. Asia-Pacific

6.4.1. Key market trends and opportunities
6.4.2. Market analysis, by country

6.4.2.1. Japan

6.4.2.1.1. Japan market size and forecast, by product type
6.4.2.1.2. Japan market size and forecast, by distribution channel

6.4.2.2. China

6.4.2.2.1. China market size and forecast, by product type
6.4.2.2.2. China market size and forecast, by distribution channel

6.4.2.3. India

6.4.2.3.1. India market size and forecast, by product type
6.4.2.3.2. India market size and forecast, by distribution channel

6.4.2.4. Rest of Asia-Pacific

6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by product type
6.4.2.4.2. Rest of Asia-Pacific market size and forecast, by distribution channel

6.4.3. Asia-Pacific market size and forecast, by product type
6.4.4. Asia-Pacific market size and forecast, by distribution channel

6.5. LAMEA

6.5.1. Key market trends and opportunities
6.5.2. Market analysis, by country

6.5.2.1. Brazil

6.5.2.1.1. Brazil market size and forecast, by product type
6.5.2.1.2. Brazil market size and forecast, by distribution channel

6.5.2.2. South Africa

6.5.2.2.1. South Africa market size and forecast, by product type
6.5.2.2.2. South Africa market size and forecast, by distribution channel

6.5.2.3. Saudi Arabia

6.5.2.3.1. Saudi Arabia market size and forecast, by product type
6.5.2.3.2. Saudi Arabia market size and forecast, by distribution channel

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Rest of LAMEA market size and forecast, by product type
6.5.2.4.2. Rest of LAMEA market size and forecast, by distribution channel

6.5.3. LAMEA market size and forecast, by product type
6.5.4. LAMEA market size and forecast, by distribution channel

CHAPTER 7: COMPANY PROFILES

7.1. AstraZeneca Plc

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. BioCryst Pharmaceuticals, Inc.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance

7.3. Daiichi Sankyo Company, Limited

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance

7.4. F. Hoffmann-La Roche AG

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. GlaxoSmithKline Plc

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments

7.6. MYLAN N.V

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance

7.7. NATCO Pharma Limited

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments

7.8. NOVARTIS AG

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance

7.9. SANOFI

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance

7.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance

LIST OF TABLES

TABLE 01. GLOBAL INFLUENZA TREATMENT MARKET, BY PRODUCT TYPE, 2018–2026 ($MILLION)
TABLE 02. PERAMIVIR INFLUENZA TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. ZANAMIVIR INFLUENZA TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. OSELTAMIVIR PHOSPHATE INFLUENZA TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. BALOXAVIR MARBOXIL INFLUENZA TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. OTHER PRODUCTS INFLUENZA TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. GLOBAL INFLUENZA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026 ($MILLION)
TABLE 08. RETAIL PHARMACY INFLUENZA TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. HSOPITAL PHARMACY INFLUENZA TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 10. OTHERS INFLUENZA TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 11. INFLUENZA TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 12. NORTH AMERICA INFLUENZA TREATMENT MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 13. U.S. INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 14. U.S. INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 15. CANADA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 16. CANADA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 17. MEXICO INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 18. MEXICO INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 19. NORTH AMERICA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026($MILLION)
TABLE 20. NORTH AMERICA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026($MILLION)
TABLE 21. EUROPE INFLUENZA TREATMENT MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 22. GERMANY INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 23. GERMANY INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 24. FRANCE INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 25. FRANCE INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 26. UK INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 27. UK INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 28. ITALY INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 29. ITALY INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 30. REST OF EUROPE INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 31. REST OF EUROPE INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 32. EUROPE INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026($MILLION)
TABLE 33. EUROPE INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026($MILLION)
TABLE 34. ASIA-PACIFIC INFLUENZA TREATMENT MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 35. JAPAN INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 36. JAPAN INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 37. CHINA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 38. CHINA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 39. INDIA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 40. INDIA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 41. REST OF ASIA-PACIFIC INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 42. REST OF ASIA-PACIFIC INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 43. ASIA-PACIFIC INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026($MILLION)
TABLE 44. ASIA-PACIFIC INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026($MILLION)
TABLE 45. LAMEA INFLUENZA TREATMENT MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 46. BRAZIL INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 47. BRAZIL INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 48. SOUTH AFRICA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 49. SOUTH AFRICA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 50. SAUDI ARABIA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 51. SAUDI ARABIA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 52. REST OF ASIA-PACIFIC INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026 ($MILLION)
TABLE 53. REST OF LAMEA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 54. LAMEA INFLUENZA TREATMENT MARKET REVENUE, BY PRODUCT TYPE, 2019–2026($MILLION)
TABLE 55. LAMEA INFLUENZA TREATMENT MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026($MILLION)
TABLE 56. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 57. ASTRAZENECA: OPERATING SEGMENTS
TABLE 58. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 59. BIOCRYST: COMPANY SNAPSHOT
TABLE 60. BIOCRYST: OPERATING SEGMENTS
TABLE 61. BIOCRYST: PRODUCT PORTFOLIO
TABLE 62. DAIICHI-SANKYO: COMPANY SNAPSHOT
TABLE 63. DAIICHI-SANKYO: OPERATING SEGMENTS
TABLE 64. DAIICHI-SANKYO: PRODUCT PORTFOLIO
TABLE 65. ROCHE: COMPANY SNAPSHOT
TABLE 66. ROCHE: OPERATING SEGMENTS
TABLE 67. ROCHE: PRODUCT PORTFOLIO
TABLE 68. GSK: COMPANY SNAPSHOT
TABLE 69. GSK: OPERATING SEGMENTS
TABLE 70. GSK: PRODUCT PORTFOLIO
TABLE 71. MYLAN: COMPANY SNAPSHOT
TABLE 72. MYLAN: OPERATING SEGMENTS
TABLE 73. MYLAN: PRODUCT PORTFOLIO
TABLE 74. NATCO: SNAPSHOT
TABLE 75. NATCO PHARMA LIMITED: OPERATING SEGMENTS
TABLE 76. NATCO PHARMA LIMITED: PRODUCT PORTFOLIO
TABLE 77. NOVARTIS: COMPANY SNAPSHOT
TABLE 78. NOVARTIS AG.: OPERATING SEGMENTS
TABLE 79. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 80. SANOFI: COMPANY SNAPSHOT
TABLE 81. SANOFI: PRODUCT SEGMENTS
TABLE 82. SANOFI: PRODUCT PORTFOLIO
TABLE 83. TEVA: COMPANY SNAPSHOT
TABLE 84. TEVA: OPERATING SEGMENTS
TABLE 85. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO:

LIST OF FIGURES

FIGURE 01. GLOBAL INFLUENZA TREATMENT MARKET SEGMENTATION
FIGURE 02. TOP PLAYER POSITIONING, 2018
FIGURE 03. TOP INVESTMENT POCKETS
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. HIGH INTENSITY OF RIVALRY
FIGURE 08. LOW THREAT OF NEW ENTRANT
FIGURE 09. IMPACT ANALYSES, INFLUENZA TREATMENT MARKET
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF PERAMIVIR INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ZANAMIVIR INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF OSELTAMIVIR PHOSPHATE INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BALOXAVIR MARBOXIL INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF OTHER PRODUCTS INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACY INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF OTHERS INFLUENZA TREATMENT MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. U.S. INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 19. CANADA INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 20. MEXICO INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 21. GERMANY INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 22. FRANCE INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 23. UK INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 24. ITALY INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 25. REST OF EUROPE INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 26. JAPAN INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 27. CHINA INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 28. INDIA INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 29. REST OF ASIA-PACIFIC INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 30. BRAZIL INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 31. SOUTH AFRICA INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 32. SAUDI ARABIA INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 33. REST OF LAMEA INFLUENZA TREATMENT MARKET, 2018–2026 ($MILLION)
FIGURE 34. ASTRAZENECA: NET SALES, 2017–2019 ($MILLION)
FIGURE 35. ASTRAZENECA: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 36. BIOCRYST: NET SALES, 2016–2018 ($MILLION)
FIGURE 37. DAIICHI-SANKYO: NET SALES, 2016–2018 ($MILLION)
FIGURE 38. DAIICHI-SANKYO: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 39. DAIICHI-SANKYO: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 40. ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 41. ROCHE: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 42. ROCHE: REVENUE SHARE BY REGION, 2018(%)
FIGURE 43. GSK: NET SALES, 2017–2018 ($MILLION)
FIGURE 44. GSK: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 45. GSK: REVENUE SHARE BY REGIONS, 2018 (%)
FIGURE 46. MYLAN: NET SALES, 2016–2018 ($MILLION)
FIGURE 47. MYLAN: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 48. MYLAN: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 49. NATCO: NET SALES, 2016–2018 ($MILLION)
FIGURE 50. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 51. NOVARTIS: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 52. NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 53. SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 54. SANOFI: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 55. SANOFI: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 56. TEVA: NET SALES, 2016–2018 ($MILLION)
FIGURE 57. TEVA: REVENUE SHARE BY REGION, 2018 (%)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[インフルエンザ治療の世界市場:製品種類別(ペラミビル、ザナミビル、リン酸オセルタミビル、バロキサビルマルボキシル、その他)、流通経路別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆